Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 15/20 | 0.37 |
| ▸ | FEN1 | P39748 | 15/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724375 | 0.83 | FEN1 (0.40) | ALOX5APFEN1AAK1 | |
| SCHEMBL15724371 | 0.77 | FEN1 (0.45) | ALOX5APFEN1MAP4K4TGFBR1 | |
| SCHEMBL15723914 | 0.76 | PTPN5 (0.40) | MAP4K4 | |
| SCHEMBL18853997 | 0.76 | ALOX5AP (0.45) | ALOX5APFEN1AAK1 | |
| SCHEMBL27305756 | 0.76 | TRPM8 (0.37) | — | |
| SCHEMBL15730880 | 0.73 | MKNK1 (0.46) | ALOX5APFEN1SCN9ATGFBR1 | |
| SCHEMBL15723959 | 0.72 | FEN1 (0.45) | ALOX5APFEN1TGFBR1 | |
| SCHEMBL18854065 | 0.71 | ALDH1A1 (0.46) | TGFBR1 | |
| SCHEMBL18853922 | 0.71 | ALOX5AP (0.40) | ALOX5APFEN1TGFBR1 | |
| SCHEMBL15723932 | 0.70 | RIPK1 (0.37) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ALOX5AP 1825/4885FEN1 2354/4885SCN9A 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.